Earnings Feed
Start Free
CYTOKINETICS INC·4

Mar 17, 4:06 PM ET

Hessekiel Jeffrey 4

4 · CYTOKINETICS INC · Filed Mar 17, 2026

Research Summary

AI-generated summary of this filing

Updated

CYTOKINETICS (CYTK) CLO Jeffrey Hessekiel Receives Equity Awards

What Happened
Jeffrey Hessekiel, Chief Legal & Administrative Officer of Cytokinetics (CYTK), received annual equity awards on 2026-03-15 totaling 51,791 shares/equivalents: 20,646 restricted stock units (RSUs) and two sets of stock options for 8,325 and 22,820 shares, respectively. All items are reported as acquired at $0.00 per unit (these are grant entries, not open‑market purchases or sales). These awards are compensation grants, not immediate cash receipts or dispositions.

Key Details

  • Transaction date: 2026-03-15; Form 4 filed 2026-03-17 (appears filed within the regulatory two-business-day window).
  • Grants reported:
    • 20,646 RSUs (footnote F1) — recorded $0.00 per share.
    • 8,325 stock options (footnote F2) — recorded $0.00 per option (derivative).
    • 22,820 stock options (footnote F3) — recorded $0.00 per option (derivative).
  • Shares/ownership after the transaction: not specified in the provided filing excerpt.
  • Plan: Awards subject to the company’s Amended and Restated 2004 Equity Incentive Plan (per footnotes).

Context

  • RSUs convert 1:1 to common shares and vest over three years (40% at year 1, 40% at year 2, 20% at year 3), subject to continued employment (F1).
  • The stock options vest in 48 equal monthly installments, subject to continued employment (F2, F3). As option grants, they are derivative rights to acquire shares upon vesting/exercise — not immediate share ownership.
  • These are routine annual compensation awards for an executive and do not by themselves indicate a purchase or sale signal.

Insider Transaction Report

Form 4
Period: 2026-03-15
CYTOKINETICS INCCYTK
Hessekiel Jeffrey
Chief Legal & Admin Officer
Transactions
  • Award

    Common Stock

    [F1]
    2026-03-15+20,646→ 107,943 total
  • Award

    Incentive Stock Option (Right to Buy)

    [F2]
    2026-03-15+8,325→ 8,325 total
    Exercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (8,325 underlying)
  • Award

    Non-Qualified Stock Option (Right to Buy)

    [F3]
    2026-03-15+22,820→ 22,820 total
    Exercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (22,820 underlying)
Footnotes (3)
  • [F1]Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
  • [F2]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
  • [F3]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
Signature
/s/ John O. Faurescu, attorney-in-fact for Mr. Hessekiel|2026-03-17

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT